Thrombolysis with recombinant tissue plasminogen activator in 7 children.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, vol.19, no.5, pp.574-7, 2013 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 19 Issue: 5
- Publication Date: 2013
- Doi Number: 10.1177/1076029612441053
- Journal Name: Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Page Numbers: pp.574-7
- Keywords: r-tPA, children, CARDIAC PATHOLOGY, CHILDHOOD, THROMBOSIS, REGISTRY, THERAPY
- Bursa Uludag University Affiliated: Yes
Abstract
The information about the thromboembolic events, the optimal treatment choice, the dose, and duration of antithrombotic therapy in children are limited. More clinical data are required. Recombinant tissue plasminogen activator (r-tPA) is increasingly used in pediatric thrombosis. We retrospectively analyzed the clinical course of 7 children (9.3 +/- 2.1 years; 34 days to 16 years) with arterial thrombosis (n = 1) and intracardiac thrombosis (n = 6). The children were treated with r-tPA. The dose ranged between 0.2 and 0.4 mg/kg per h infused for 3 to 4 hours. This dose was repeated between 2 to 7 times till the thrombolysis was achieved. Treatment side effects were closely monitored. Complete clot lysis was achieved in all cases. None of them had severe bleeding except mild recurrent epistaxis occurring in 2 cases. In conclusion, r-tPA is an effective and safe therapy under close hemostatic control in children.